Ardent Health price target raised to $21 from $18 at Loop Capital

Loop Capital analyst Timothy Greaves raised the firm’s price target on Ardent Health to $21 from $18 and keeps a Buy rating on the shares after its Q2 results. The firm is positive on the company’s stronger-than-expected volumes and lower costs, adding that its updated outlook assumes higher revenues and improved margins throughout the year, the analyst tells investors in a research note. Ardent is also benefiting from improved reimbursement rates, favorable payor mix, and increased supplemental revenue, the firm added.